Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001144204-19-019104
Filing Date
2019-04-10
Accepted
2019-04-10 17:28:30
Documents
6
Effectiveness Date
2019-04-10

Document Format Files

Seq Description Document Type Size
1 DEFA14A tv518648_defa14a.htm DEFA14A 26637
2 GRAPHIC tv518648_001.jpg GRAPHIC 85587
3 GRAPHIC tv518648_002.jpg GRAPHIC 141296
4 GRAPHIC tv518648_003.jpg GRAPHIC 54405
5 GRAPHIC tv518648_004.jpg GRAPHIC 35102
6 GRAPHIC tv518648_005.jpg GRAPHIC 4558
  Complete submission text file 0001144204-19-019104.txt   467785
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 19742369
SIC: 2834 Pharmaceutical Preparations